Group 1 - The core point of the news is that China Universal Asset Management has announced a subscription limit for two of its funds, the China Universal Science and Technology Innovation Fund and the China Universal Medical Innovation Fund, starting from August 11, to protect existing investors and maintain stable operations [1] - The China Universal Science and Technology Innovation Fund, managed by Shao Jie, has achieved a return rate of 132.55% since inception, with an annualized return of 14.79% for Class A shares and 39.66% with an annualized return of 13.11% for Class C shares [1] - The China Universal Medical Innovation Fund, managed by renowned fund manager Ge Lan, has a return rate of 68.74% for Class A shares and 60.24% for Class C shares since inception, with annualized returns of 8.45% and 7.59% respectively [1] Group 2 - The China Universal Science and Technology Innovation Fund focuses on the technology innovation industry, with significant investments in sectors such as smart vehicles, advanced manufacturing processes, and self-developed chip IP [2] - The top ten holdings of the China Universal Science and Technology Innovation Fund include companies like Hengxuan Technology, Lanyin Technology, and Tencent Holdings, with total market values ranging from approximately 117 million to 350 million yuan [2] - The China Universal Medical Innovation Fund primarily invests in stocks related to medical innovation, with a focus on innovative pharmaceuticals and medical devices [2][4] Group 3 - The top ten holdings of the China Universal Medical Innovation Fund include companies such as Sanofi Pharmaceutical and WuXi AppTec, with market values ranging from approximately 324 million to 729 million yuan [4] - Other funds managed by different companies, such as ICBC Credit Suisse and Great Wall Fund, have also reported high returns this year, with notable investments in similar sectors [5][6]

Core Viewpoint - The recent trend of "purchase limits" in the public fund industry reflects a shift towards controlling fund size to ensure effective investment strategies and protect the interests of existing investors [1][4]. Group 1: Fund Performance and Purchase Limits - Several high-performing active equity funds have announced limits on large subscriptions, with approximately 50 funds implementing such measures since July [1]. - Notable funds include the China Europe Medical Innovation Fund, managed by Ge Lan, which has a year-to-date return of over 87%, and the China Europe Science and Technology Innovation Fund, managed by Shao Jie, with a return of 84.33% [2][4]. - The purchase limits range from 50,000 to 1 million yuan, aimed at controlling fund size and maintaining performance [2][4]. Group 2: Rationale Behind Purchase Limits - The primary reason for implementing purchase limits is to balance fund size and returns, as rapid inflows can dilute existing investors' returns and affect the fund manager's ability to adjust portfolios effectively [4]. - The limits are also intended to protect investors from potential market volatility, encouraging rational investment behavior and reducing the risk of "buying high and selling low" [4][5]. Group 3: Industry Shift Towards Quality - The current purchase limit trend indicates a transition in the fund industry from a focus on size competition to prioritizing quality and effective strategies [5]. - Fund managers are increasingly emphasizing long-term investment principles over short-term size expansion, as seen in the consistent purchase limits on Ge Lan's medical funds and similar actions by emerging fund managers [5].